Collegium Pharmaceutical (NASDAQ:COLL) announced a record-breaking 2025, driven by strong net revenue and adjusted EBITDA performance. The company highlighted the significant growth of its ADHD product, JORNAY PM, which saw a 48.9% year-over-year increase. This performance was bolstered by a roughly 20% volume expansion, a strategic increase in its salesforce from 125 to 180 representatives, and targeted commercial initiatives. The company presented its outlook at the Barclays Miami Conference, emphasizing the continued momentum of JORNAY PM and the resilience of its pain management portfolio.
Management Recaps a Record 2025
CEO Vikram Karnani stated that 2025 was a landmark year, achieving record net revenues and adjusted EBITDA. He detailed progress on three key strategic priorities: accelerating JORNAY PM‘s growth, ensuring the durability of the company’s pain franchise, and maintaining disciplined capital deployment. Karnani noted that Collegium Pharmaceutical raised its financial guidance twice during the year, with actual performance consistently exceeding updated expectations.
The pain franchise, which includes products like Nucynta, Xtampza, and Belbuca, also demonstrated growth, increasing by 6% year-over-year. This stability in the pain portfolio is crucial as the company navigates upcoming generic competition for Nucynta.
JORNAY PM Growth Drivers and Commercial Initiatives
Management attributed JORNAY PM‘s outperformance in 2025 to both substantial volume growth, estimated at around 20% year-over-year, and an improved net price. These gains were supported by expanded commercial efforts and strategic timing of campaigns around the back-to-school season. Improvements in the “gross-to-net” revenue accounting also contributed to the strong financial results.
Chief Commercial Officer Scott Dreyer elaborated on JORNAY PM‘s competitive advantages in the ADHD market. He pointed to its unique once-nightly dosing and its efficacy upon awakening, addressing a critical unmet need for morning symptom control in both pediatric and adult patients. Collegium Pharmaceutical has focused on increasing physician awareness and reaching patients and caregivers through an expanded sales force and robust digital marketing strategies.
2026 Outlook and Financial Strategy
Looking ahead to 2026, Collegium Pharmaceutical projects total revenue between $805 million and $825 million. JORNAY PM is expected to be a primary growth engine, with revenue anticipated to reach $190 million to $200 million, representing approximately 31% growth at the midpoint. This projection is primarily driven by increasing prescription demand.
The company generated over $325 million in free cash flow in 2025. To optimize its financial structure, Collegium Pharmaceutical recently refinanced its debt, lowering its cost of capital to SOFR+275. Management indicated that the company possesses balance sheet capacity for approximately $1 billion in transactions. Strategic priorities for capital deployment include business development opportunities, opportunistic share buybacks, and further debt reduction.
Our Analysis
Collegium Pharmaceutical‘s strategic focus on JORNAY PM appears to be paying off, with significant growth in both volume and revenue. The company’s ability to expand its salesforce and execute targeted commercial initiatives demonstrates effective market penetration. While the pain franchise faces generic pressures, its stability provides a solid foundation. The strong free cash flow generation and available capital position Collegium for potential strategic acquisitions or further debt management, indicating a disciplined approach to growth and financial health.
Fonte: Yahoo Finance
